))
Colchicine Unveiled: A New Dawn in Cardiovascular Prevention
Manage episode 384014773 series 3393216
Contenu fourni par Baptist Health. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Baptist Health ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Join Baptist Health Miami Cardiac & Vascular Institute experts Jonathan Fialkow, M.D., FACC, Adedapo (Dapo) Iluyomade, M.D., and Sergiu Darabant, M.D. as they discuss how this development could revolutionize the approach to combating cardiometabolic diseases through targeting inflammation, and what it means for your patients.
In this enlightening episode, we delve into the groundbreaking FDA approval of colchicine for the prevention of major adverse cardiovascular events. Join us as we explore the journey of this ancient remedy, traditionally used for gout, now emerging as a promising agent in cardioprotection. We dissect the pivotal clinical trials and evidence-based data that led to this landmark decision, shedding light on colchicine's mechanism of action and its potential role in reshaping preventive cardiology.
Guests:
Jonathan Fialkow, M.D., FACC
Chief Medical Executive for Population Health, Value and Primary Care
Deputy Director of Miami Cardiac & Vascular Institute
Chief of Cardiology, Baptist Hospital
Adedapo (Dapo) Iluyomade, M.D., Preventive Cardiologist, Baptist Health Miami Cardiac & Vascular Institute
Sergiu Darabant, M.D., Cardiologist, Baptist Health Miami Cardiac & Vascular Institute
21 episodes
Partager
